Anne M. Rompalo, MD

CRS:

JHU

Role:

Investigators

Position:

HPTN Site Leader

Email:

arompalo@jhmi.edu

Anne M. Rompalo, M.D., Sc.M.  Dr. Rompalo is a Professor of Medicine and Gynecology at the Johns Hopkins University School of Medicine (JHUSOM), with joint appointments in Epidemiology, International Health and Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health.  She is Medical Director of the CDC-sponsored Sexually Transmitted Diseases (STD)/HIV Prevention Training Center at Johns Hopkins (PTC), and has previously been Acting Medical Director of the Baltimore City Health Departments STD Clinics and Medical Director of the Office of Population Affairs Male Training Center.  She has over 15 years of experience as the Medical Director of the STD/HIV PTC, and has been a key investigator on several studies focused on the natural history of HIV among women including the HERS (HIV Epidemiology Research Study) and HIV prevention among U.S. women at high risk for infection, HPTN 064 trial. 

  • Investigator of Record, HPTN 064
  • Investigator of Record, HPTN 083

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5384: A Phase II, Randomized, Open-Label Trial of a...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More